Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRXNASDAQ:IMVTNASDAQ:PRVLNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$11.00-0.4%$8.85$5.92▼$11.31$2.30B1.083.03 million shs2.41 million shsIMVTImmunovant$16.03+4.5%$14.82$12.72▼$34.47$2.74B0.611.19 million shs666,879 shsPRVLPrevail Therapeutics$23.00$23.01$9.02▼$23.35$787.66M1.59955,800 shsN/ASRRKScholar Rock$34.29+11.3%$30.25$6.76▼$46.98$3.25B0.371.27 million shs1.77 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-1.34%+4.55%+0.09%+40.46%+63.80%IMVTImmunovant-0.65%+8.79%+0.79%-21.41%-39.20%PRVLPrevail Therapeutics0.00%0.00%0.00%0.00%0.00%SRRKScholar Rock-0.39%+6.79%-5.37%-14.70%+214.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCRXBioCryst Pharmaceuticals4.3695 of 5 stars4.41.00.04.23.31.70.6IMVTImmunovant1.4997 of 5 stars3.50.00.00.02.81.70.0PRVLPrevail TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASRRKScholar Rock4.3695 of 5 stars3.62.00.04.43.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.89Moderate Buy$16.5650.57% UpsideIMVTImmunovant 2.90Moderate Buy$38.33139.21% UpsidePRVLPrevail Therapeutics 0.00N/AN/AN/ASRRKScholar Rock 3.14Buy$42.6724.44% UpsideCurrent Analyst Ratings BreakdownLatest PRVL, SRRK, IMVT, and BCRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025SRRKScholar RockLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/7/2025BCRXBioCryst PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.005/6/2025BCRXBioCryst PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $17.005/6/2025BCRXBioCryst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/29/2025BCRXBioCryst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$20.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.004/11/2025BCRXBioCryst PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.004/10/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$503.49M4.57N/AN/A($2.22) per share-4.95IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/APRVLPrevail TherapeuticsN/AN/AN/AN/A$4.85 per shareN/ASRRKScholar Rock$33.19M98.09N/AN/A$3.12 per share10.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$226.54M-$0.26N/AN/AN/A-30.01%N/A-24.06%8/4/2025 (Estimated)IMVTImmunovant-$259.34M-$2.74N/AN/AN/AN/A-77.94%-69.82%8/5/2025 (Estimated)PRVLPrevail Therapeutics-$63.19M-$2.22N/AN/AN/AN/A-55.57%-48.14%N/ASRRKScholar Rock-$165.79M-$2.53N/AN/AN/AN/A-145.60%-91.83%8/14/2025 (Estimated)Latest PRVL, SRRK, IMVT, and BCRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/APRVLPrevail TherapeuticsN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.782.73IMVTImmunovantN/A6.046.04PRVLPrevail TherapeuticsN/A7.567.56SRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%IMVTImmunovant47.08%PRVLPrevail Therapeutics86.80%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals4.80%IMVTImmunovant5.90%PRVLPrevail Therapeutics57.20%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.25 million197.19 millionOptionableIMVTImmunovant120170.92 million159.84 millionOptionablePRVLPrevail Therapeutics6634.25 millionN/ANot OptionableSRRKScholar Rock14094.95 million75.64 millionOptionablePRVL, SRRK, IMVT, and BCRX HeadlinesRecent News About These CompaniesScholar Rock (NASDAQ:SRRK) Trading 5.9% Higher - Here's WhyJune 5 at 3:18 PM | marketbeat.comLifesci Capital Comments on Scholar Rock Q2 EarningsJune 5 at 5:52 AM | marketbeat.comLifesci Capital Upgrades Scholar Rock (NASDAQ:SRRK) to Strong-BuyJune 4 at 6:09 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 3 at 3:57 AM | marketbeat.comScholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General ManagerJune 2 at 7:26 PM | uk.finance.yahoo.com20,188 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Acquired by Squarepoint Ops LLCJune 2 at 4:07 AM | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Director Michael Gilman Sells 3,375 SharesMay 31, 2025 | marketbeat.comJoshua Reed Sells 5,400 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) StockMay 31, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Director Kristina Burow Sells 5,400 SharesMay 31, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 6,075 SharesMay 31, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells $200,610.00 in StockMay 31, 2025 | marketbeat.comInsider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells 3,375 Shares of StockMay 31, 2025 | insidertrades.comScholar Rock (NASDAQ:SRRK) Shares Down 6.2% - What's Next?May 30, 2025 | marketbeat.comWellington Management Group LLP Has $74.58 Million Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)May 30, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Receives $42.67 Average Target Price from BrokeragesMay 30, 2025 | americanbankingnews.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Sold by Polar Asset Management Partners Inc.May 29, 2025 | marketbeat.comMillennium Management LLC Sells 524,642 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 29, 2025 | marketbeat.comScholar Rock to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | businesswire.comNuveen Asset Management LLC Buys 122,638 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)May 28, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Given Average Rating of "Buy" by BrokeragesMay 28, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Shares Purchased by Voloridge Investment Management LLCMay 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRVL, SRRK, IMVT, and BCRX Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$10.98 -0.06 (-0.59%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Immunovant NASDAQ:IMVT$16.05 +0.71 (+4.60%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Prevail Therapeutics NASDAQ:PRVLPrevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.Scholar Rock NASDAQ:SRRK$34.29 +3.47 (+11.27%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
